

# Feng-Cai Zhu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3182438/publications.pdf>

Version: 2024-02-01

55  
papers

4,515  
citations

394421

19  
h-index

189892

50  
g-index

58  
all docs

58  
docs citations

58  
times ranked

7894  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. <i>Lancet</i> , The, 2020, 395, 1845-1854.	13.7	1,127
2	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2020, 396, 479-488.	13.7	1,011
3	Co-infection with respiratory pathogens among COVID-2019 cases. <i>Virus Research</i> , 2020, 285, 198005.	2.2	419
4	Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China. <i>New England Journal of Medicine</i> , 2014, 370, 818-828.	27.0	379
5	Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. <i>Journal of Infectious Diseases</i> , 2020, 222, 746-754.	4.0	262
6	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 483-495.	9.1	232
7	Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virus. <i>Nature Communications</i> , 2014, 5, 3142.	12.8	145
8	Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2022, 399, 237-248.	13.7	143
9	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. <i>Nature Medicine</i> , 2021, 27, 1062-1070.	30.7	114
10	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. <i>Nature Medicine</i> , 2022, 28, 401-409.	30.7	113
11	Safety and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e783-e791.	5.8	71
12	2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 56-63.	4.0	52
13	Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. <i>Emerging Microbes and Infections</i> , 2021, 10, 365-375.	6.5	33
14	A reverse-transcription recombinase-aided amplification assay for the rapid detection of N gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Virology</i> , 2020, 549, 1-4.	2.4	29
15	Seroepidemiology of hepatitis B virus infection and impact of vaccination. <i>World Journal of Gastroenterology</i> , 2015, 21, 7842.	3.3	28
16	Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients. <i>Microbiology Spectrum</i> , 2021, 9, e0059021.	3.0	27
17	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003953.	8.4	27
18	Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 271.	17.1	25

#	ARTICLE	IF	CITATIONS
19	Rapid and Sensitive Detection of Salmonella spp. Using CRISPR-Cas13a Combined With Recombinase Polymerase Amplification. <i>Frontiers in Microbiology</i> , 2021, 12, 732426.	3.5	23
20	Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 916-921.	3.3	20
21	Severe human infection with a novel avian-origin influenza A(H7N4) virus. <i>Science Bulletin</i> , 2018, 63, 1043-1050.	9.0	19
22	Pyroptosis induced by enterovirus A71 infection in cultured human neuroblastoma cells. <i>Virology</i> , 2018, 521, 69-76.	2.4	18
23	Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage. <i>Nature Communications</i> , 2020, 11, 4421.	12.8	18
24	Identification and genetic characterization of a novel circular single-stranded DNA virus in a human upper respiratory tract sample. <i>Archives of Virology</i> , 2017, 162, 3305-3312.	2.1	17
25	Environmental Risk Factors and Geographic Distribution of Severe Fever with Thrombocytopenia Syndrome in Jiangsu Province, China. <i>Vector-Borne and Zoonotic Diseases</i> , 2019, 19, 758-766.	1.5	14
26	Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B. <i>Nature Communications</i> , 2020, 11, 4419.	12.8	13
27	Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis. <i>Expert Review of Vaccines</i> , 2021, 20, 1-11.	4.4	13
28	Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis. <i>Frontiers in Immunology</i> , 2020, 11, 595970.	4.8	12
29	Adjuvantation helps to optimise COVID-19 vaccine candidate. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 891-893.	9.1	11
30	MicroRNA-195 suppresses enterovirus A71-induced pyroptosis in human neuroblastoma cells through targeting NLRX1. <i>Virus Research</i> , 2021, 292, 198245.	2.2	10
31	A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months. <i>Expert Review of Vaccines</i> , 2018, 17, 257-262.	4.4	9
32	Influenza surveillance in China: a big jump, but further to go. <i>Lancet Public Health</i> , The, 2019, 4, e436-e437.	10.0	8
33	Advances in the progress of monoclonal antibodies for rabies. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	3.3	8
34	Rapid detection of human mastadenovirus species B by recombinase polymerase amplification assay. <i>BMC Microbiology</i> , 2019, 19, 8.	3.3	7
35	An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2101-2106.	3.3	7
36	Willingness of parents to vaccinate their 6-60-month-old children with EV71 vaccines: a cross-sectional study in rural areas of northern Jiangsu Province. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1579-1585.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	3.3	5
38	Waning immunity and potential asymptomatic infection in 3-7 years old children who received one dose of measles-mumps-rubella vaccine: A 4-year prospective study. <i>Vaccine</i> , 2021, 39, 3509-3515.	3.8	4
39	Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. <i>Chinese Medical Journal</i> , 2021, 134, 2037-2044.	2.3	4
40	The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months. <i>Expert Review of Vaccines</i> , 2017, 16, 515-524.	4.4	3
41	Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19. <i>Lancet</i> , The, 2021, 398, 2134-2135.	13.7	3
42	Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	3.3	3
43	<sc>AntiV&#x2013;NSN</sc> : a universal antiviral strategy to combat both <sc>RNA</sc> and <sc>DNA</sc> viruses by destroying their nucleic acids without sequence limitation. <i>Microbial Biotechnology</i> , 0, , .	4.2	3
44	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. <i>Advances in Therapy</i> , 2022, 39, 3789-3798.	2.9	3
45	Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease. <i>Lancet Rheumatology</i> , The, 2022, 4, e77-e78.	3.9	2
46	Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	3.3	2
47	The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 916-917.	9.1	2
48	Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens. <i>Emerging Microbes and Infections</i> , 2022, 11, 1751-1753.	6.5	2
49	The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir. <i>Virology</i> , 2019, 536, 58-67.	2.4	1
50	Whole exome sequencing reveals the different responsiveness to Enterovirus 71 vaccination in Chinese children. <i>International Journal of Infectious Diseases</i> , 2020, 97, 47-53.	3.3	1
51	Immune persistence induced by three doses of 60 µg hepatitis B vaccine in non-responders following standard primary vaccination in Chinese adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2762-2767.	3.3	1
52	Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines. <i>Engineering</i> , 2021, 7, 903-907.	6.7	1
53	Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa181.	0.9	0
54	Editorial: Hepatitis B virus infection and risk of nonalcoholic fatty liver disease: A population-based cohort study&#x2013;authors' reply. <i>Liver International</i> , 2020, 40, 1502-1503.	3.9	0

#	ARTICLE	IF	CITATIONS
55	A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	0